Compare Amgen, Inc. (AMGN) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Xylem, Inc. — how do they compare? Amgen, Inc. trades at $417.37 (market cap $224.14B), while Xylem, Inc. trades at $122.25 (market cap $28.76B). The key difference: Amgen, Inc. is far larger — about 7.8× Xylem, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | XYL | |
|---|---|---|
Market Cap | $224.14B | $28.76B |
Sector | Health | Industrials |
52-Week High | $417.20 | $152.95 |
52-Week Low | $271.18 | $106.34 |
Enterprise Value | $267.45B | $30.54B |
Dividend Yield | 2.43% | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
XYL trades at $121.59, up 0.33% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin expanding to 10.59%. Recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water technology presence, while AI-driven demand for water-treatment equipment supports growth.
The outlook is positive, with a consensus price target of $150.43 implying 24% upside, backed by margin expansion and strategic acquisitions. Risks include execution of integration and potential revenue delays from electric metering projects, as noted in Q2 2026 results. Analyst sentiment is mixed but leans bullish, with 47.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
